Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - ASTROTECH Corp | c03439e8vk.htm |
Exhibit 99.1
 |
 |
FOR IMMEDIATE RELEASE
ASTROTECH COMPLETES REVIEW OF STRATEGIC ALTERNATIVES
Austin, Texas, July 14, 2010 — Astrotech Corporation (NASDAQ: ASTC), a leading provider of
commercial aerospace services, today announced that it has concluded its engagement with Lazard
Middle Market following a review of strategic alternatives by its board of directors.
On September 28, 2009 Astrotech announced that it engaged Lazard Middle Market to advise the Company in exploring
strategic financial and business alternatives to enhance shareholder value. Astrotech will
continue to consider potential strategic alternatives, while maintaining focus on advancing its
core business, Astrotech Space Operations (ASO) and its new business initiatives at 1st
Detect and Astrogenetix.
About Astrotech Corporation
Astrotech Corporation (Nasdaq: ASTC) is a commercial aerospace company that provides spacecraft payload processing and government services, designs and manufactures space hardware, and commercializes space technologies for use on Earth. The Company serves our government and commercial satellite and spacecraft customers with our pre-launch services from our Astrotech Space Operations (ASO) subsidiary and incubates space technology businesses now focusing on two companies: 1st Detect Corporation, which is developing a mini-mass spectrometer first developed for the International Space Station; and Astrogenetix, Inc., which is developing biotech products in space and has recently developed a vaccine candidate for Salmonella.
Astrotech Corporation (Nasdaq: ASTC) is a commercial aerospace company that provides spacecraft payload processing and government services, designs and manufactures space hardware, and commercializes space technologies for use on Earth. The Company serves our government and commercial satellite and spacecraft customers with our pre-launch services from our Astrotech Space Operations (ASO) subsidiary and incubates space technology businesses now focusing on two companies: 1st Detect Corporation, which is developing a mini-mass spectrometer first developed for the International Space Station; and Astrogenetix, Inc., which is developing biotech products in space and has recently developed a vaccine candidate for Salmonella.
The statements in this document may contain forward-looking statements that are made pursuant to
the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are subject to risks, trends, and uncertainties that could cause actual
results to be materially different from the forward-looking statement. These factors include, but
are not limited to, continued government support and funding for key space programs, product
performance and market acceptance of products and services, as well as other risk factors and
business considerations described in the company’s Securities & Exchange Commission filings
including the annual report on Form 10-K. Any forward-looking statements in this document should be
evaluated in light of these important risk factors. The Company assumes no obligation to update
these forward-looking statements.
###